Corvus Pharmaceuticals SG&A Expense (Quarterly) Analysis

Corvus Pharmaceuticals Inc (CRVS)

2.06 -0.01 (-0.48%) USD | NASDAQ | May 24, 16:00

2.06 0.00 (0.00%) After-Hours: 20:00

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2015. Upgrade now.

Date	Value
March 31, 2024	2.178M
December 31, 2023	1.652M
September 30, 2023	1.595M
June 30, 2023	1.654M
March 31, 2023	1.98M
December 31, 2022	1.586M
September 30, 2022	2.108M
June 30, 2022	2.09M
March 31, 2022	2.313M
December 31, 2021	2.022M
September 30, 2021	2.056M
June 30, 2021	2.184M
March 31, 2021	3.253M
December 31, 2020	2.688M
September 30, 2020	3.226M
June 30, 2020	2.91M
March 31, 2020	3.106M
December 31, 2019	2.52M
September 30, 2019	2.517M

Date	Value
June 30, 2019	2.956M
March 31, 2019	2.886M
December 31, 2018	2.777M
September 30, 2018	2.775M
June 30, 2018	2.543M
March 31, 2018	2.541M
December 31, 2017	2.501M
September 30, 2017	2.211M
June 30, 2017	2.788M
March 31, 2017	2.72M
December 31, 2016	2.118M
September 30, 2016	2.769M
June 30, 2016	1.706M
March 31, 2016	1.029M
December 31, 2015	1.195M
September 30, 2015	0.606M
June 30, 2015	0.327M
March 31, 2015	0.29M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

1.586M

Minimum

Dec 2022

3.253M

Maximum

Mar 2021

2.330M

Average

2.181M

Median

SG&A Expense (Quarterly) Benchmarks